Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from HC Wainwright

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $200.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 59.88% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday. Wells Fargo & Company cut their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $125.10 on Friday. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a 50 day moving average price of $112.92 and a two-hundred day moving average price of $110.52. The firm has a market capitalization of $7.56 billion, a P/E ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Coldstream Capital Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares in the last quarter. MidWestOne Financial Group Inc. raised its position in shares of Jazz Pharmaceuticals by 5.4% during the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock valued at $2,458,000 after buying an additional 1,134 shares in the last quarter. Barclays PLC lifted its holdings in shares of Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock worth $4,369,000 after acquiring an additional 6,289 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in Jazz Pharmaceuticals in the third quarter valued at $2,491,000. Finally, XTX Topco Ltd raised its position in Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 4,245 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.